| Similar Articles |
|---|
 |
The Motley Fool
July 20, 2009
Brian Orelli |
Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.   |
The Motley Fool
September 20, 2007
Brian Orelli |
Teva's Disappointing Phase 2 Results Teva's lupus drug fails to meet its primary endpoint in its phase 2 trial. Investors, take note. |
The Motley Fool
June 12, 2009
Brian Orelli |
Where Good Drugs Go to Die Human Genome Sciences has the potential to pop if Benlysta's phase 3 trials are a success, but tread lightly, history is not on their side. |
The Motley Fool
August 28, 2009
Brian Orelli |
Is There Life After a 714% Return? It doesn't get any less risky for Immunomedics. |
The Motley Fool
October 30, 2009
Brian Orelli |
Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
The Motley Fool
November 2, 2009
Brian Orelli |
Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed. |
Chemistry World
November 4, 2009
Phil Taylor |
New treatment hope for lupus patients GlaxoSmithKline and Human Genome Sciences' Benlysta (belimumab), works by blocking the production of autoantibodies by plasma B-cells, the immune system's primary antibody-producing cells. |
The Motley Fool
April 14, 2011
Brian Orelli |
Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year. |
The Motley Fool
April 30, 2008
Brian Lawler |
A Tale of 2 DNA Drugs More trouble for Genentech's No. 2 product, the systemic lupus treatment Rituxan. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
March 3, 2010
Brian Orelli |
A Costly Missed Connection Dimebon's phase 3 failure costs Medivation shareholders 67%. |
The Motley Fool
October 26, 2011
Brian Orelli |
Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest. |
The Motley Fool
June 5, 2009
Brian Orelli |
Failure! Merck said today that rolofylline failed to show an effect in its phase 3 clinical trial in heart failure patients. |
The Motley Fool
March 30, 2010
Brian Orelli |
Invest in This Space at Your Own Risk Lung cancer is a tough foe for drugmakers. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
November 12, 2010
Brian Orelli |
Benlysta: Not Perfect, but Good Enough Human Genome should get past the FDA advisory panel next week. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
The Motley Fool
November 17, 2010
Brian Orelli |
52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval. |
The Motley Fool
July 28, 2010
Jordan DiPietro |
3 Biotechs on Your Radar Screen It's not easy keeping track of all the drugs coming in and out of the development pipeline, but if you can stay up to date, you often have an advantage |
The Motley Fool
November 14, 2011
Brian Orelli |
Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
The Motley Fool
October 5, 2010
Brian Orelli |
You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
The Motley Fool
August 19, 2010
Brian Orelli |
High Risk, High Reward. At Least It Was Cheap! Biogen licenses a drug to treat ALS. |
The Motley Fool
March 21, 2011
Brian Orelli |
Let's See Some Data, Curis Curis investors seem to have shrugged off the multiple unknowns and embraced the potential for the company's skin cancer drug. |
The Motley Fool
December 30, 2011
Brian Orelli |
A Bad Year for the 6,300% Miracle Human Genome Sciences falls from grace. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
May 19, 2010
Brian Orelli |
The Biggest-Little Biotechs in the World If you do decide to invest in these biotechs before they've secured phase 3 results make sure you know what you're getting yourself into and aren't blindly following the crowd. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
March 30, 2005
Stephen D. Simpson |
Clinical Trials Cost Biotechs More The failure of edifoligide means little to Bristol-Myers, but a great deal to Corgentech. In the grand scheme of things, there's not much new here -- the large, well-stocked pharmaceutical goes on its way, and the biotech stock gets pummeled. |
The Motley Fool
September 10, 2010
Brian D. Pacampara |
A Potential Blockbuster Roars Ahead Johnson & Johnson made a good choice to purchase Cougar Biotechnology. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
December 31, 2010
Brian Orelli |
2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions. |
The Motley Fool
March 11, 2010
Jim Mueller |
Is Medivation a Buy? What is the thinking with regards to Medivation today? It already got a big haircut last week. Is it worth investing in at these lower prices? |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
November 19, 2010
Brian Orelli |
Exelixis: Up 32% With Room to Run It was only a phase 2 trial, after all. |
The Motley Fool
September 2, 2011
Brian Orelli |
Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
The Motley Fool
May 29, 2008
Brian Lawler |
Human Genome's Jam-Packed Pipeline This drugmaker has plentiful candidates heading for phase 3 testing. |
